BCM
ESPR

Bayesian Capital Management’s Esperion Therapeutics ESPR Stock Holding History

Bayesian Capital Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-65,900
Closed -$145K – 717
2024
Q4 		$145K Buy
+65,900
New +$154K 0.02% 596
2024
Q2 		– Sell
-51,200
Closed -$137K – 847
2024
Q1 		$137K Buy
+51,200
New +$124K 0.01% 693
2023
Q4 		– Sell
-17,600
Closed -$17.2K – 834
2023
Q3 		$17.2K Buy
+17,600
New +$25.5K ﹤0.01% 655
2022
Q4 		– Sell
-27,630
Closed -$185K – 849
2022
Q3 		$185K Buy
+27,630
New +$190K 0.04% 532
2022
Q2 		– Sell
-29,795
Closed -$138K – 863
2022
Q1 		$138K Buy
+29,795
New +$128K 0.02% 679
2018
Q2 		– Sell
-3,199
Closed -$231K – 638
2018
Q1 		$231K Buy
+3,199
New +$235K 0.06% 463
2017
Q4 		– Sell
-11,127
Closed -$558K – 592
2017
Q3 		$558K Buy
+11,127
New +$537K 0.13% 247

Other funds holding ESPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PCM
PenderFund Capital Management Vancouver, British Columbia, Canada $780M AUM 24.84% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Bayesian Capital Management's ESPR Position: Q1 2025 in Review

Bayesian Capital Management sold out of Esperion Therapeutics (ESPR) in Q1 2025, closing a stake of 65,900 shares — an estimated $145K sold.

Bayesian Capital Management first reported a position in ESPR in Q3 2017 and held it in 7 quarters. The position peaked at $558K in Q3 2017. 186 funds tracked by Wall St. Rank hold ESPR as of Q1 2025.

  • Bayesian Capital Management reported no remaining Esperion Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Bayesian Capital Management sold 65,900 Esperion Therapeutics shares in Q1 2025, an estimated $145K.
  • Bayesian Capital Management first reported a position in Esperion Therapeutics in Q3 2017 and held it in 7 quarters.
  • Bayesian Capital Management's Esperion Therapeutics position peaked at $558K in Q3 2017.
  • 186 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2025.

Based on Bayesian Capital Management's 13F filing for Q1 2025, filed 15 May 2025.